Shots:

• The P-III study is designed to assess caregivers’ perspectives on the long-term seizure & non-seizure-related benefits of Fintepla on patients with Dravet syndrome and on their caregivers and families
• Results: seizure-related benefits noted by caregivers include a reduction in frequency- seizure activity- and shorter recovery time while non-seizure benefits include improvements in executive functions such as cognition (76%)- learning- problem-solving (56%)- mood (41%)- sleep quality (47%)- motor function (46%) and speech (48%)
• The caregivers themselves felt less stress (66%) anxiety- and depression (68%)- with 62% of employed parents missing less work- sleep improved (71%). Family benefits showed improvement in behavior and/or mood of siblings (58%)

  Ref: GlobeNewswire | Image: Zogenix